DOCSLIB.ORG

Hodgkin Lymphoma Source: Globocan 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hodgkin Lymphoma Source: Globocan 2020 Hodgkin lymphoma Source: Globocan 2020 Number of new cases in 2020, both sexes, all ages Number of deaths in 2020, both sexes, all ages Breast 2 261 419 Lung 1 796 144 Lung 2 206 771 Colorectum 935 173 Colorectum 1 931 590 Liver 830 180 Prostate 1 414 259 Stomach 768 793 Stomach 1 089 103 Breast 684 996 Liver 905 677 Oesophagus 544 076 Cervix uteri 604 127 Pancreas 466 003 Oesophagus 604 100 Prostate 375 304 Thyroid 586 202 Cervix uteri 341 831 Bladder 573 278 Leukaemia 311 594 Non-Hodgkin lymphoma 544 352 Non-Hodgkin lymphoma 259 793 Pancreas 495 773 Brain, central nervous system 251 329 Leukaemia 474 519 Bladder 212 536 Kidney 431 288 Ovary 207 252 Corpus uteri 417 367 Kidney 179 368 Lip, oral cavity 377 713 Lip, oral cavity 177 757 Melanoma of skin 324 635 Multiple myeloma 117 077 Ovary 313 959 Larynx 99 840 Brain, central nervous system 308 102 Corpus uteri 97 370 Larynx 184 615 Gallbladder 84 695 Multiple myeloma 176 404 Nasopharynx 80 008 Nasopharynx 133 354 Melanoma of skin 57 043 Gallbladder 115 949 Oropharynx 48 143 Oropharynx 98 412 Thyroid 43 646 Hypopharynx 84 254 Hypopharynx 38 599 Hodgkin lymphoma 83 087 Mesothelioma 26 278 Testis 74 458 Hodgkin lymphoma 23 376 Salivary glands 53 583 Salivary glands 22 778 Vulva 45 240 Vulva 17 427 Penis 36 068 Kaposi sarcoma 15 086 Kaposi sarcoma 34 270 Penis 13 211 Mesothelioma 30 870 Testis 9 334 Vagina 17 908 Vagina 7 995 0 500 000 1 000 000 1 500 000 2 000 000 0 500 000 1 000 000 1 500 000 Cancer incidence and mortality statistics worldwide and by region Incidence Mortality Both sexes Males Females Both sexes Males Females Cum. risk Cum. risk Cum. risk Cum. risk Cum. risk Cum. risk New cases New cases New cases Deaths Deaths Deaths 0-74 (%) 0-74 (%) 0-74 (%) 0-74 (%) 0-74 (%) 0-74 (%) Eastern Africa 2 930 0.07 1 768 0.08 1 162 0.05 1 334 0.04 811 0.05 523 0.03 Middle Africa 639 0.04 392 0.05 247 0.03 303 0.03 186 0.03 117 0.02 Northern Africa 3 719 0.13 2 118 0.16 1 601 0.11 1 204 0.04 716 0.05 488 0.02 Southern Africa 712 0.09 403 0.10 309 0.07 175 0.03 108 0.03 67 0.02 Western Africa 2 815 0.08 1 705 0.09 1 110 0.06 1 299 0.04 789 0.06 510 0.03 Caribbean 655 0.12 371 0.14 284 0.10 235 0.04 139 0.05 96 0.03 Central America 2 888 0.13 1 686 0.17 1 202 0.11 798 0.04 476 0.05 322 0.03 South America 7 091 0.12 4 173 0.15 2 918 0.10 1 802 0.03 1 056 0.04 746 0.03 Northern America 9 077 0.18 5 144 0.20 3 933 0.15 1 064 0.02 633 0.02 431 0.01 Eastern Asia 9 172 0.04 6 174 0.05 2 998 0.03 3 195 0.01 2 115 0.02 1 080 0.01 South-Eastern Asia 3 197 0.04 1 990 0.06 1 207 0.03 1 016 0.02 656 0.02 360 0.01 South-Central Asia 14 158 0.07 8 523 0.08 5 635 0.06 5 315 0.03 3 320 0.03 1 995 0.02 Western Asia 5 215 0.16 3 007 0.18 2 208 0.14 1 553 0.06 923 0.07 630 0.05 Central and Eastern Europe 6 299 0.16 3 162 0.17 3 137 0.15 1 724 0.04 951 0.05 773 0.03 Western Europe 5 590 0.20 3 351 0.24 2 239 0.17 745 0.02 467 0.02 278 0.01 Southern Europe 4 681 0.22 2 617 0.25 2 064 0.20 973 0.03 556 0.04 417 0.02 Northern Europe 3 288 0.22 1 872 0.26 1 416 0.19 511 0.02 305 0.03 206 0.02 Australia and New Zealand 896 0.22 484 0.23 412 0.20 110 0.02 67 0.02 43 0.01 Melanesia 65 0.05 41 0.08 24 0.03 20 0.02 14 0.03 6 0.01 Polynesia 0 0 0 0 0 0 0 0 0 0 0 0 Micronesia 0 0 0 0 0 0 0 0 0 0 0 0 Low HDI 6 812 0.07 4 139 0.09 2 673 0.06 3 135 0.04 1 931 0.05 1 204 0.03 Medium HDI 15 752 0.06 9 323 0.07 6 429 0.05 5 974 0.03 3 646 0.03 2 328 0.02 High HDI 25 408 0.07 15 249 0.08 10 159 0.05 8 144 0.02 5 101 0.03 3 043 0.02 Very high HDI 35 098 0.16 20 260 0.19 14 838 0.14 6 123 0.02 3 610 0.03 2 513 0.02 World 83 087 0.09 48 981 0.10 34 106 0.07 23 376 0.02 14 288 0.03 9 088 0.02 Incidence, both sexes Mortality, both sexes 5-year prevalence, both sexes N.America* N.America* Oceania (10.9%) (4.6%) (1.4%) Asia LAC** Asia LAC** Africa (35.1%) (12.8%) (38.2%) (12.1%) (9.8%) Asia Africa Europe (47.4%) LAC** (13%) (16.9%) (12.6%) N.America* Europe Africa (13.3%) Europe (23.9%) (18.5%) (27.8%) Population Number Population Number Population Number Asia 31 742 Asia 11 079 Asia 98 618 Europe 19 858 Africa 4 315 Europe 78 086 Africa 10 815 Europe 3 953 *Northern America 37 336 **Latin America and the Caribbean 10 634 **Latin America and the Caribbean 2 835 **Latin America and the Caribbean 35 456 *Northern America 9 077 *Northern America 1 064 Africa 27 682 Oceania 961 Oceania 130 Oceania 3 934 Total 83 087 Total 23 376 Total 281 112 The Global Cancer Observatory - All Rights Reserved, December, 2020. Page 1 Age standardized (World) incidence rates, hodgkin lymphoma, males, all ages ≥ 2.6 1.9–2.6 1.3–1.9 0.83–1.3 Not applicable 0.45–0.83 No data < 0.45 Age standardized (World) incidence rates, hodgkin lymphoma, females, all ages ≥ 2.1 1.5–2.1 0.89–1.5 0.51–0.89 Not applicable 0.25–0.51 No data < 0.25 Data source: GLOBOCAN 2020 Graph production: IARC (https://gco.iarc.fr/today) World Health Organization © International Agency for Research on Cancer 2020 Age standardized (World) incidence rates, hodgkin lymphoma, by sex Age standardized (World) incidence and mortality rates, hodgkin lymphoma Males Females Incidence Mortality Southern Europe 3.1 2.5 Southern Europe 2.8 0.31 Western Europe 3.0 2.1 Northern Europe 2.6 0.23 Northern Europe 3.0 2.3 Australia and New Zealand 2.6 0.18 Australia and New Zealand 2.7 2.5 Western Europe 2.5 0.17 Northern America 2.4 1.9 Northern America 2.1 0.15 Western Asia 2.1 1.6 Central and Eastern Europe 2.0 0.40 Central and Eastern Europe 2.1 1.9 Western Asia 1.9 0.59 Central America 1.9 1.2 Northern Africa 1.6 0.53 Northern Africa 1.8 1.3 Central America 1.5 0.42 South America 1.8 1.2 South America 1.5 0.35 Caribbean 1.6 1.1 Caribbean 1.3 0.41 Southern Africa 1.2 0.86 Southern Africa 1.0 0.27 World 1.2 0.80 World 0.98 0.26 Western Africa 1.1 0.67 Western Africa 0.86 0.45 Eastern Africa 0.94 0.61 Eastern Africa 0.77 0.39 South-Central Asia 0.84 0.57 South-Central Asia 0.71 0.27 Melanesia 0.78 0.40 Melanesia 0.59 0.20 South-Eastern Asia 0.59 0.33 Middle Africa 0.46 0.24 Middle Africa 0.57 0.36 South-Eastern Asia 0.45 0.14 Eastern Asia 0.57 0.31 Eastern Asia 0.44 0.13 Polynesia Polynesia Micronesia Micronesia 6.0 5.0 4.0 3.0 2.0 1.0 0 1.0 2.0 3.0 4.0 5.0 6.0 6.0 5.0 4.0 3.0 2.0 1.0 0 1.0 2.0 3.0 4.0 5.0 6.0 ASR (World) per 100 000 ASR (World) per 100 000 The Global Cancer Observatory - All Rights Reserved, December, 2020. Page 2.
Load more

Recommended publications
  • Follicular Lymphoma
    Follicular Lymphoma What is follicular lymphoma? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines FOLLICULAR LYMPHOMA: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of follicular lymphoma and appreciate the best treatment choices available according to the subtype of follicular lymphoma. We recommend that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease. The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of newly diagnosed and relapsed follicular lymphoma. This guide for patients has been produced in collaboration with ESMO and is disseminated with the permission of ESMO. It has been written by a medical doctor and reviewed by two oncologists from ESMO including the lead author of the clinical practice guidelines for professionals, as well as two oncology nurses from the European Oncology Nursing Society (EONS). It has also been reviewed by patient representatives from ESMO’s Cancer Patient Working Group. More information about the Anticancer Fund: www.anticancerfund.org More information about the European Society for Medical Oncology: www.esmo.org For words marked with an asterisk, a definition is provided at the end of the document. Follicular Lymphoma: a guide for patients - Information based on ESMO Clinical Practice Guidelines – v.2014.1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO.
    [Show full text]
  • Follicular Lymphoma with Leukemic Phase at Diagnosis: a Series Of
    Leukemia Research 37 (2013) 1116–1119 Contents lists available at SciVerse ScienceDirect Leukemia Research journa l homepage: www.elsevier.com/locate/leukres Follicular lymphoma with leukemic phase at diagnosis: A series of seven cases and review of the literature a c c c c Brady E. Beltran , Pilar Quinones˜ , Domingo Morales , Jose C. Alva , Roberto N. Miranda , d e e b,∗ Gary Lu , Bijal D. Shah , Eduardo M. Sotomayor , Jorge J. Castillo a Department of Oncology and Radiotherapy, Edgardo Rebagliati Martins Hospital, Lima, Peru b Division of Hematology and Oncology, Rhode Island Hospital, Brown University Alpert Medical School, Providence, RI, USA c Department of Pathology, Edgardo Rebaglati Martins Hospital, Lima, Peru d Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA e Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA a r t i c l e i n f o a b s t r a c t Article history: Follicular lymphoma (FL) is a prevalent type of non-Hodgkin lymphoma in the United States and Europe. Received 23 April 2013 Although, FL typically presents with nodal involvement, extranodal sites are less common, and leukemic Received in revised form 25 May 2013 phase at diagnosis is rare. There is mounting evidence that leukemic presentation portends a worse Accepted 26 May 2013 prognosis in patients with FL. We describe 7 patients with a pathological diagnosis of FL who presented Available online 20 June 2013 with a leukemic phase. We compared our cases with 24 additional cases reported in the literature. Based on our results, patients who present with leukemic FL tend to have higher risk disease.
    [Show full text]
  • Non-Hodgkin Lymphoma Booklet
    Understanding Non-Hodgkin Lymphoma A Guide for Patients, Survivors, and Loved Ones October 2017 Lymphoma Research Foundation (LRF) Helpline and Clinical Trials Information Service CONTACT THE LRF HELPLINE Trained staff are available to answer questions and provide support to patients, caregivers and healthcare professionals in any language. Our support services include: • Information on lymphoma, treatment options, side effect management and current research fi ndings • Financial assistance for eligible patients and referrals for additional fi nancial, legal and insurance help • Clinical trial searches based on patient’s diagnosis and treatment history • Support through LRF’s Lymphoma Support Network, a national one-to one volunteer patient peer program Monday through Friday, Toll-Free (800) 500-9976 or email [email protected] Understanding Non-Hodgkin Lymphoma A Guide For Patients, Survivors, and Loved Ones October 2017 This guide is an educational resource compiled by the Lymphoma Research Foundation to provide general information on adult non- Hodgkin lymphoma. Publication of this information is not intended to replace individualized medical care or the advice of a patient’s doctor. Patients are strongly encouraged to talk to their doctors for complete information on how their disease should be diagnosed, treated, and followed. Before starting treatment, patients should discuss the potential benefits and side effects of cancer therapies with their physician. Contact the Lymphoma Research Foundation Helpline: (800) 500-9976 [email protected] Website: www.lymphoma.org Email: [email protected] This patient guide is supported through unrestricted educational grants from: © 2017 Lymphoma Research Foundation. Information contained herein is the property of the Lymphoma Research Foundation (LRF).
    [Show full text]
  • MINI-REVIEW Large Cell Lymphoma Complicating Persistent Polyclonal B
    Leukemia (1998) 12, 1026–1030 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu MINI-REVIEW Large cell lymphoma complicating persistent polyclonal B cell lymphocytosis J Roy1, C Ryckman1, V Bernier2, R Whittom3 and R Delage1 1Division of Hematology, 2Department of Pathology, Saint Sacrement Hospital, 3Division of Hematology, CHUQ, Saint Franc¸ois d’Assise Hospital, Laval University, Quebec City, Canada Persistent polyclonal B cell lymphocytosis (PPBL) is a rare immunoglobulin (Ig) M with a polyclonal pattern on protein lymphoproliferative disorder of unclear natural history and its electropheresis. Flow cytometry cell analysis displays the pres- potential for B cell malignancy remains unknown. We describe the case of a 39-year-old female who presented with stage IV- ence of the CD19 antigen and surface IgM with a normal B large cell lymphoma 19 years after an initial diagnosis of kappa/lambda ratio. In contrast to CLL, CD5 is absent. There PPBL; her disease was rapidly fatal despite intensive chemo- is an association between HLA-DR 7 and PPBL in more than therapy and blood stem cell transplantation. Because we had two-thirds of the patients but the reason for such an associ- recently identified multiple bcl-2/lg gene rearrangements in ation remains unclear.3,6 There has been one report of PPBL blood mononuclear cells of patients with PPBL, we sought evi- occurring in identical female twins.7 No other obvious genetic dence of this oncogene in this particular patient: bcl-2/lg gene rearrangements were found in blood mononuclear cells but not predisposition or familial inheritance has yet been described in lymphoma cells.
    [Show full text]
  • Hodgkin Lymphoma
    Hodgkin Lymphoma Erica, Hodgkin lymphoma survivor Revised 2016 Publication Update Hodgkin Lymphoma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about blood cancer treatment. See below for important new information that was not available at the time this publication was printed. In May 2017, the Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for the treatment of adult patients with classical Hodgkin lymphoma (HL) that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation (HSCT). It is also approved for the treatment of adult patients with classical HL that has relapsed or progressed after autologous HSCT and brentuximab vedotin. These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. In March 2017, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. For more information, contact an Information Specialist at (800) 955-4572 or [email protected]. Information Specialists: 800.955.4572 I www.LLS.org PS57 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to finding cures for blood cancer patients.
    [Show full text]
  • Lymphoproliferative Disorders
    Lymphoproliferative disorders Dr. Mansour Aljabry Definition Lymphoproliferative disorders Several clinical conditions in which lymphocytes are produced in excessive quantities ( Lymphocytosis) Lymphoma Malignant lymphoid mass involving the lymphoid tissues (± other tissues e.g : skin ,GIT ,CNS …) Lymphoid leukemia Malignant proliferation of lymphoid cells in Bone marrow and peripheral blood (± other tissues e.g : lymph nods ,spleen , skin ,GIT ,CNS …) Lymphoproliferative disorders Autoimmune Infection Malignant Lymphocytosis 1- Viral infection : •Infectious mononucleosis ,cytomegalovirus ,rubella, hepatitis, adenoviruses, varicella…. 2- Some bacterial infection: (Pertussis ,brucellosis …) 3-Immune : SLE , Allergic drug reactions 4- Other conditions:, splenectomy, dermatitis ,hyperthyroidism metastatic carcinoma….) 5- Chronic lymphocytic leukemia (CLL) 6-Other lymphomas: Mantle cell lymphoma ,Hodgkin lymphoma… Infectious mononucleosis An acute, infectious disease, caused by Epstein-Barr virus and characterized by • fever • swollen lymph nodes (painful) • Sore throat, • atypical lymphocyte • Affect young people ( usually) Malignant Lymphoproliferative Disorders ALL CLL Lymphomas MM naïve B-lymphocytes Plasma Lymphoid cells progenitor T-lymphocytes AML Myeloproliferative disorders Hematopoietic Myeloid Neutrophils stem cell progenitor Eosinophils Basophils Monocytes Platelets Red cells Malignant Lymphoproliferative disorders Immature Mature ALL Lymphoma Lymphoid leukemia CLL Hairy cell leukemia Non Hodgkin lymphoma Hodgkin lymphoma T- prolymphocytic
    [Show full text]
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015
    NCCN Guidelines Index NHL Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . Peripheral T-Cell Lymphomas NCCN Guidelines Version 2.2015 NCCN Guidelines Index NHL Table of Contents Peripheral T-Cell Lymphomas Discussion DIAGNOSIS SUBTYPES ESSENTIAL: · Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic. · An FNA alone is not sufficient for the initial diagnosis of peripheral T-cell lymphoma. Subtypes included: · Adequate immunophenotyping to establish diagnosisa,b · Peripheral T-cell lymphoma (PTCL), NOS > IHC panel: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, · Angioimmunoblastic T-cell lymphoma (AITL)d See Workup CD4, CD8, CD7, CD56, CD57 CD21, CD23, EBER-ISH, ALK · Anaplastic large cell lymphoma (ALCL), ALK positive (TCEL-2) or · ALCL, ALK negative > Cell surface marker analysis by flow cytometry: · Enteropathy-associated T-cell lymphoma (EATL) kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRαβ; TCRγ Subtypesnot included: · Primary cutaneous ALCL USEFUL UNDER CERTAIN CIRCUMSTANCES: · All other T-cell lymphomas · Molecular analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants · Additional immunohistochemical studies to establish Extranodal NK/T-cell lymphoma, nasal type (See NKTL-1) lymphoma subtype:βγ F1, TCR-C M1, CD279/PD1, CXCL-13 · Cytogenetics to establish clonality · Assessment of HTLV-1c serology in at-risk populations.
    [Show full text]
  • Hodgkin's Disease Variant of Richter's Syndrome in Chronic Lymphocytic Leukaemia Patients Previously Treated with Fludarabin
    research paper Hodgkin’s disease variant of Richter’s syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine Dominic Fong,1 Alexandra Kaiser,2 Summary Gilbert Spizzo,1 Guenther Gastl,1 Alexandar Tzankov2 The transformation of chronic lymphocytic leukaemia (CLL) into large-cell 1Division of Haematology and Oncology and lymphoma (Richter’s syndrome, RS) is a well-documented phenomenon. 2Department of Pathology, Innsbruck Medical Only rarely does CLL transform into Hodgkin’s lymphoma (HL). To further University, Innsbruck, Austria analyse the clinico-pathological and genetic findings in the HL variant of RS, we performed a single-institution study in four patients, who developed HL within a mean of 107 months after diagnosis of CLL. All were treated with fludarabine. Three cases were Epstein–Barr virus (EBV)-associated mixed cellularity (MC) HL, the fourth was nodular sclerosis (NS) HL without EBV association. The sites involved by HL included supra- and infradiaphragmal lymph nodes and the tonsils; stage IV disease was also documented. All patients presented with CLL treatment-resistant lymphadenopathies and B- symptoms. In two of the MC cases, molecular analysis performed on CLL samples and microdissected Hodgkin and Reed–Sternberg cells (HRSC) suggested a clonal relationship, while in NS no indication of a clonal relationship was detected. In summary, HL can occur in CLL patients at any Received 15 December 2004; accepted for site, up to 17 years after initial diagnosis, especially after treatment with publication 1 February 2005 fludarabine. The majority present with B-symptoms and CLL treatment- Correspondence: A. Tzankov MD, Department resistant lymphadenopathy, are of the MC type, clonally related to CLL and of Pathology, Innsbruck Medical University, might be triggered by an EBV infection.
    [Show full text]
  • Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Lymphoma (SLL)
    Helpline (freephone) 0808 808 5555 [email protected] www.lymphoma-action.org.uk Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) This information is about chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are different forms of the same illness. They are often grouped together as a type of slow-growing (low-grade or indolent) non-Hodgkin lymphoma. On this page What is CLL/SLL? Who gets CLL? Symptoms of CLL Diagnosis and staging Outlook Treatment Follow-up Relapsed or refractory CLL Research and targeted treatments We have separate information about the topics in bold font. Please get in touch if you’d like to request copies or if you would like further information about any aspect of lymphoma. Phone 0808 808 5555 or email [email protected]. Page 1 of 13 © Lymphoma Action What is CLL/SLL? Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing types of blood cancer. They develop when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). CLL and SLL are different forms of the same illness. They develop when B cells that don’t work properly build up in your body. • In CLL, the abnormal B cells build up in your blood and bone marrow. This is why it’s called ‘leukaemia’ – after ‘leucocytes’: the medical name for white blood cells.
    [Show full text]
  • Non-Hodgkin Lymphoma
    Non-Hodgkin Lymphoma Rick, non-Hodgkin lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) believes we are living at an extraordinary moment. LLS is committed to bringing you the most up-to-date blood cancer information. We know how important it is for you to have an accurate understanding of your diagnosis, treatment and support options. An important part of our mission is bringing you the latest information about advances in treatment for non-Hodgkin lymphoma, so you can work with your healthcare team to determine the best options for the best outcomes. Our vision is that one day the great majority of people who have been diagnosed with non-Hodgkin lymphoma will be cured or will be able to manage their disease with a good quality of life. We hope that the information in this publication will help you along your journey. LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, education and patient services. Since 1954, LLS has been a driving force behind almost every treatment breakthrough for patients with blood cancers, and we have awarded almost $1 billion to fund blood cancer research. Our commitment to pioneering science has contributed to an unprecedented rise in survival rates for people with many different blood cancers. Until there is a cure, LLS will continue to invest in research, patient support programs and services that improve the quality of life for patients and families.
    [Show full text]
  • Second Malignancies After Treatment of Childhood Non-Hodgkin Lymphoma – a Report of the Berlin-Frankfurt-Muenster Study Group
    ARTICLE Non-Hodgkin Lymphoma Ferrata Storti Foundation Second malignancies after treatment of childhood non-Hodgkin lymphoma – a report of the Berlin-Frankfurt-Muenster study group Olga Moser,1 Martin Zimmermann,2 Ulrike Meyer,3 Wolfram Klapper,4 Ilske Oschlies,4 Martin Schrappe,5 Andishe Attarbaschi,6 Georg Mann,6 Felix Niggli,7 Claudia Spix,8 Udo Kontny,1 Thomas Klingebiel,9 Alfred Reiter,3 Birgit Burkhardt10 and Wilhelm Woessmann11 Haematologica 2021 1Division of Pediatric Hematology and Oncology, RWTH-Aachen University, Aachen, Volume 106(5):1390-1400 Germany; 2Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany; 3Department of Pediatric Hematology and Oncology, Justus Liebig- University Giessen, Giessen, Germany; 4Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany; 5Department of Pediatric Hematology and Oncology, Children’s University Hospital, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany; 6Department of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; 7Department of Pediatric Hematology and Oncology, Children’s University Hospital Zurich, Zurich, Switzerland; 8German Childhood Cancer Registry (GCCR) at Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI) of the Mainz University Medical Center, Mainz, Germany; 9Department of Pediatric Hematology and
    [Show full text]
  • Acute Lymphoblastic Leukemia Following Hodgkin's Disease
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 10, No. 2 Copyright © 1980, Institute for Clinical Science, Inc. Acute Lymphoblastic Leukemia Following Hodgkin’s Disease ABDUS SALEEM, M.D.* and ROSALIE L. JOHNSTON, M.D. Departments of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030 ABSTRACT Over 100 instances of acute leukemia have been reported in the course of Hodgkin’s disease. The type of leukemia almost always is nonlympho- blastic. Only five well documented cases of acute lymphoblastic leukemia (ALL) have been found by us in the world literature. One case who de­ veloped ALL six years after intensive radiotherapy for Hodgkin’s disease is herewith reported. The patient responded to treatment with Predisone, Vincristine and intrathecal methotrexate and maintained a complete remis­ sion on 6-mercaptopurine for nine months. When last seen, the bone marrow revealed a mild increase in blasts indicative of an early relapse. The incidence of second malignancy cervical area. He was treated initially with developing in the course of Hodgkin’s penicillin but had no significant im­ disease (HD) has been reported from 1.6 provement. An excisional node biopsy to 2.2 percent.1,13,14 Acute non-lympho- was performed and a diagnosis of blastic leukemias (ANLL) are among the Hodgkin’s disease, mixed cellularity, was commonest second tumors.2,14 There is made. The general architecture of the some controversy in the literature lymph node was partially effaced, though whether acute lymphoblastic leukemia several germinal centers were still pres­ (ALL) occurs in the course of Hodgkin’s ent.
    [Show full text]